U.S. Markets open in 9 hrs 27 mins

How Will Histogenics Shareholders Fare in the Merger with Ocugen

NEW YORK, NY / ACCESSWIRE / April 30, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Histogenics Corporation (HSGX), a clinical-stage company, focuses on the development of restorative cell therapies. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.

On April 8th, the company announced that they have entered into a definitive merger agreement with Ocugen. The proposed merger will result in a combined publicly-traded, clinical-stage biopharmaceutical company operating under the Ocugen name.

Read the details of the proposed merger that could impact shareholders READ MORE

Copyand paste to your browser may be required to view the report - https://tradersnewssource.com/histogenics-2/

"Since Ocugen's founding, we have sought to develop innovative therapies to treat rare and underserved eye diseases through a combination of therapeutic approaches that utilize small molecules, biologics, and gene therapies," said Shankar Musunuri, Ph.D., M.B.A., Chairman, Chief Executive Officer and Co-Founder of Ocugen.

Getmore info on Ocugen including a rundown of their product pipeline READ MORE

Copyand paste to your browser may be required to view the report - https://tradersnewssource.com/histogenics-2/

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://www.tradersnewssource.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

CONTACT: editor@tradersnewssource.com

SOURCE: Traders News Source



View source version on accesswire.com:
https://www.accesswire.com/543451/How-Will-Histogenics-Shareholders-Fare-in-the-Merger-with-Ocugen